BROOMFIELD — Aktiv Pharma Group has secured a federal grant for development of an autoinjector for prehospital treatment of severe bleeding.
The grant from the U.S. Department of Defense is valued at $1,265,562 and will go toward continued development of a tranexamic acid autoinjector. Tranexamic acid is a medicine that controls bleeding by blocking the breakdown of blood clots.
The grant came through the Department of Defense’s Defense Health Agency.
“We are excited to receive this support from the U.S. Government to develop yet another one of the critically important emergency treatment products” company founder and CEO Amir Genosar said in a prepared statement. “This award will help Aktiv continue advancing the TXA autoinjector towards FDA approval in 2025, which will ultimately be used to help protect both our troops and the civilian population.”
Aktiv has met several milestones in the autoinjector program, including development of a proprietary formulation, performing stability studies and completing several preclinical studies.
Aktiv says that uncontrolled bleeding is the No. 1 cause of death on the battlefield, with limited options for pre-hospital treatment options prior to evacuation.
Additionally, 18,400 preventable deaths occur each year in the U.S. alone due to hemorrhage after injury.
“We are proud to develop a product that will be available for the U.S. Warfighter and emergency medical responders to treat patients in the field as close as possible to the time of injury, with an autoinjector that meets and exceeds the most stringent reliability requirements of the U.S. Food and Drug Administration (FDA) for emergency-use injectors,” Genosar said.
Aktiv Pharma Group is a trade name for AktiVax Inc. The company develops drug products in a range of pre-filled delivery systems.